罗格列酮对实验性慢性环孢素肾病的作用

目的 探讨罗格列酮（RSG）对慢性环孢素肾病（CCN）大鼠模型的肾保护作用。 方法 低盐饮食基础上建立CCN大鼠模型，其中1组模型鼠用RSG同时灌胃。分别在实验开始后第14天和第35天处死动物，检测血浆和肾组织血管紧张素Ⅱ（AngⅡ）、AngⅡ1型受体(AT1R)、转化生长因子β1(TGF-β1)、细胞外调节蛋白激酶（p-ERK）、α-SMA和纤连蛋白（FN）的表达。在体外用不同浓度的CsA和RSG孵育NRK细胞。RT-PCR检测肾皮质TGF-β1，Western印迹分析检测FN、AT1R、p-ERK水平。 结果 RSG可改善环孢素A导致的大鼠肌酐清除率的下降[（0.586±0.094）比(1.072±0.105)ml&#8226;min^-1&#8226;kg^-1，P < 0.01]、血浆和肾组织AngⅡ水平增加（P < 0.01）、肾间质单核细胞浸润（P < 0.01）、肾间质纤维化（1.707±0.019 比 2.335±0.022，P < 0.01）、肾组织α-SMA表达增加（P < 0.01）、肾皮质TGF-β1 mRNA水平增加（P < 0.01）、NRK细胞FN、AT1R和p-ERK蛋白水平增加（P < 0.05）。 结论 RSG可能通过减轻炎细胞浸润、影响AngⅡ作用和下调TGF-β1等途径减轻CsA所致的肾组织损伤。     

脂肪干细胞/Ⅰ型胶原凝胶复合体的构建及其体内外成骨分化研究

目的探讨利用脂肪干细胞与Ⅰ型胶原凝胶复合构建新型骨组织工程复合体的可行性并对其体内外成骨分化情况进行分析。方法取3月龄日本大耳白兔肩胛部皮下脂肪，Ⅰ型胶原酶消化获得细胞，于体外依次进行骨、软骨、脂肪多向诱导分化鉴定；取第3代细胞与Ⅰ型胶原凝胶复合，于成骨诱导条件下体外培养，相差显微镜、扫描电镜观察复合情况并对其碱性磷酸酶、细胞外基质矿化程度进行检测，同时设立单层贴壁培养细胞作为对照（n=4）；两周后移植于裸鼠皮下，12周后处死动物，依次行放射学、组织学检测观察成骨情况（n=3）。结果（1）所获细胞具备骨、软骨、脂肪多向分化潜能，为多能干细胞。（2）形态学观察显示脂肪干细胞呈三维立体生长状态，均匀、高密度悬浮于Ⅰ型胶原凝胶中。在体外成骨诱导条件下，其碱性磷酸酶活性以及外基质矿化程度均显著高于单层贴壁培养细胞（P〈0．01，n=4）。（3）于裸鼠皮下移植12周后，放射学、组织学检测显示脂肪干细胞．Ⅰ型胶原凝胶复合体成骨明显（n=3）。结论（1）IⅠ型胶原凝胶可显著促进脂肪干细胞的成骨分化。（2）作为一种新型的骨组织工程复合物，脂肪干细胞-Ⅰ型胶原凝胶复合体可应用于骨组织工程，特别是腔隙性骨缺损的修复过程。     

明胶降解物对大鼠真皮成纤维细胞增殖及Ⅰ型胶原蛋白分泌的影响

目的 探讨组织工程心瓣膜常用人工基质材料--明胶发生降解后的产物对大鼠真皮成纤维细胞增殖及Ⅰ型胶原蛋白分泌的影响. 方法 利用酶组合技术制备明胶降解物（gelatin hydrolysate, GH）,采用超滤的方法分离出低分子量明胶降解物组分（gelatin hydrolysate fraction, GHF）,用于5只SD大鼠真皮成纤维细胞的体外培养.采用CCK-8活细胞计数试剂盒（Cell Counting Kit-8）检测细胞的增殖情况,ELISA试剂盒检测细胞I型胶原蛋白的分泌情况. 结果 ①GHF对细胞增殖作用的浓度效应：在0.125～1.0 mg/ml浓度范围内,GHF对细胞的促增殖作用呈现先增强后减弱的趋势,在0.25 mg/ml时,细胞增殖率最大,达到（47.54±16.35）%;②GH与GHF对细胞增殖影响比较：GH与GHF均具有促进细胞增殖的作用,且在浓度为0.25 mg/ml时,促细胞增殖作用无显著差异[（27.04±15.21）% vs （39.22±15.55）%, P=0.177];③GH与GHF对细胞分泌Ⅰ型胶原蛋白影响比较：GHF组第3天时Ⅰ型胶原分泌量为（28.06±5.60）pg/105,与空白对照的（18.24±4.52）pg/105相比,有显著差异（P=0.006）,而GH组直至第6天时Ⅰ型胶原蛋白分泌量,与空白对照相比,无统计学意义（P=0.103）. 结论 分子量大小不同的明胶降解物GH与GHF均具有促进大鼠真皮成纤维细胞增殖的作用,且分子量较小的GHF还具有促进细胞I型胶原分泌的功能.     

丹参在抑制兔唇创口瘢痕增生中的作用

选用50只新西兰白兔,2只处死后取上唇组织作为病理对照,48只采用Millard’s法修复上唇裂隙,拆线后随机分为实验组、溶媒组和对照组3组,每组16只。实验组每天涂擦复方丹参膏2次,溶媒组每日涂擦溶媒膏二次,对照组不作任何处理。分别在术后0d、7d、15d、21d、30d、60d、90d测量上唇瘢痕的体积变化,并在7d、30d、60d时每组分别处死2只,90d后全部处死,取上唇瘢痕组织在光镜和电镜下观察组织病理学变化。组织学观察显示丹参可抑制成纤维细胞增殖,影响胶原蛋白合成,使胶原纤维重排和降解,从而减轻瘢痕增生。     

转化生长因子-β抑制剂Decorin抗眼结膜滤过泡瘢痕形成的实验研究

目的　探讨Decorin抑制结膜下瘢痕形成的作用机制并为临床应用提供理论依据。方法　新西兰大白兔分为Decorin组、磷酸盐缓冲液 (PBS)组、正常对照组。在滤过术后第 7,14,3 0天 ,应用链酶亲和素免疫组织化学法 (SABC法 )检测各组在结膜滤过泡中转化生长因子 - β1(TGF- β1)和转化生长因子 - βⅠ型受体 (TGF - βRⅠ )的含量 ;应用天狼星玫瑰红 -偏振光法检测各组Ⅰ、Ⅲ型胶原的含量。　结果　PBS组结膜滤过泡中TGF - β1、TGF - βRⅠ免疫组化染色和Ⅰ、Ⅲ型胶原染色呈强阳性表达 ,第 3 0天明显比第 7天增强 (P <0 .0 5 ) ;Decorin组结膜滤过泡中TGF - β1、TGF - βRⅠ免疫组化染色和Ⅰ、Ⅲ型胶原染色呈弱阳性表达 ,相同时相点比较 ,Decorin组比PBS组明显呈弱表达 (P <0 .0 1)。Decorin可使滤过泡瘢痕中TGF - β1和TGF - βRⅠ活性降低 ,Ⅰ、Ⅲ型胶原的含量减少。　结论　Decorin可作为抑制滤过泡瘢痕形成的辅助药物     

Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766

The efficacy of the neurotrophic peptide ORG 2766 in diabetic patients with polyneuropathy was evaluated in a double-blind, placebo-controlled, multicentre trial. One hundred and twenty four patients were randomised in five groups to receive 0.1, 0.4, 2 or 5 mg ORG 2766 or placebo, once daily, administered subcutaneously 52 weeks. Thermal discrimination thresholds (TDT) and vibration perception thresholds (VPT), motor and sensory nerve conduction velocity, Hoffmann reflex, heart rate variation during deep breathing and heart rate response after standing up, neurological examination score and neuropathic symptom score were determined at baseline and after 17, 34 and 52 weeks of treatment. Of the nerve function indices studied, at week 52 the TDT_warmth of the hand in the ORG 2766 0.1, 0.4 and 5 mg groups and the TDT_cold of the foot in the ORG 2766 0.1 and 0.4 mg groups significantly improved compared with placebo. Further significant improvement as compared with placebo was observed in the paraesthesia score at week 34 and week 52 in the ORG 2766 2 mg group. Only at week 34 had both the heartbeat variation during deep breathing and the VPT of the foot in the ORG 2766 0.1 mg group improved significantly, compared with placebo. No further statistically significant differences were observed at time for the other measures. No adverse reactions were observed. The only recorded drug-induced side effect was pain at the injection site. Taking all measures of efficacy into account, the statistically significant results observed did not show consistency within each measure. Therefore, it is concluded that ORG 2766, in contrast to earlier reports, is not effective in treating diabetic polyneuropathy.     

C3 Deposition in IgA Nephropathy in Children and Adolescents

The aim of this study was to assess the significance of C3 deposition in IgA nephropathy in children and adolescents. One hundred and two patients aged 5–21 years (57 male and 45 female) were studied. The findings of C3 deposition were classified into 8 groups by immunofluorescent (IF) pattern and intensity as follows: group MC3+ (N = 12): mesangiocapillary pattern and 3+ in intensity; group MC2+ (N = 13): mesangiocapillary and 2+; group MC1 + (N = 4): mesangiocapillary and 1 +; group M3+ (N = 11): mesangial and 3+; group M2+ (N = 24): mesangial and 2+; group M1 + (N=18): mesangial 1 +; group S (N = 12): only segmentally positive; and group N (N = 8): negative. Histological changes were scored semiquantitatively as an activity index (cellular proliferation, necrosis, interstitial cell infiltration, and cellular crescents) and a chronicity index (mesangial sclerosis, segmental and global glomerular sclerosis, fibrous crescents, adhesion and tubulo-interstitial change). IF findings were scored semiquantitatively and laboratory findings were also studied. The following results were obtained: 1) The scores of total activity index in MC groups were higher than in the M, S or N groups, and the greater the degree of C3 deposition, the higher the score; 2) Such result was not evident in the chronicity index; 3) High IF scores of IgG and IgM were found in the MC3+ and MC2+ groups; 4) Hematuria was more severe in MC3+ and MC2+ than in other groups, and proteinuria was more prominent in the MC than other groups. Thus the degree of C3 deposition was parallel with histological activity and urinary findings.     

Pattern of renal dysfunction in analgesic nephropathy--comparison with glomerulonephritis.

Comprehensive renal function tests were performed in 84 patients with analgesic nephropathy, 33 glomerulonephritis patients matched for creatinine clearance, and 30 control subjects. A system of 1-day renal function tests including urine microscopy, creatinine clearance, phenolsulphonphthalein excretion, urine concentration and acidification, and electrolyte excretion, was used. Patients with analgesic nephropathy were found to have significant sterile pyuria and haematuria, even those with mild renal insufficiency, significantly reduced concentrating ability and a distal acidifying defect, and a tendency to impaired sodium conservation. These function defects are consistent with the primary lesion of renal papillary necrosis in analgesic nephropathy; the detection of these defects have implications in patient management.